[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615616":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":38,"responsibleParty":67,"collaborators":69,"id":71,"slug":10,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Kernel","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Accelerated TMS Cohort",null,"Participants who have previously been diagnosed with MDD and have elected to undergo accelerated TMS to treat their depression at a participating clinic will be enrolled in the study.",[13],"Other: fNIRS measurement",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy Controls Cohort","Participants with no diagnosis of depression and no depression-related treatment within the past year will be enrolled as the control group.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"OTHER","fNIRS measurement","Kernel Flow is a non-invasive neuroimaging device that uses time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure changes in cortical hemodynamics associated with brain activity.",[9,15],[25],"Kernel Flow",[27],{"name":28,"affiliation":5,"role":29},"Katherine Perdue, PhD","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Katherine Perdue, PhD VP, Applied Science & Clinical Research, PhD","CONTACT","323-238-9225","research@kernel.com",{"name":37,"role":33,"phone":34,"phoneExt":10,"email":35},"Moriah Taylor Research Project Manager",[39,53],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"NOT_YET_RECRUITING","Los Angeles","California","90232","United States",{"type":46,"coordinates":47},"Point",[48,49],-118.24368,34.05223,{"lat":49,"lon":48},[52],{"name":28,"role":29,"phone":10,"phoneExt":10,"email":10},{"facility":54,"status":55,"city":56,"state":42,"zip":57,"country":44,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Acacia Clinics","RECRUITING","Sunnyvale","94087",{"type":46,"coordinates":59},[60,61],-122.03635,37.36883,{"lat":61,"lon":60},[64],{"name":65,"role":66,"phone":10,"phoneExt":10,"email":10},"Noah DeGaetano, MD","SUB_INVESTIGATOR",{"type":68,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[70],{"name":54,"class":6},"100615616",false,"NCT07294924","Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements","PREDICT-ACC: Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements","PREDICT-ACC","Inclusion Criteria for:\n\nAccelerated TMS cohort\n\n* Adults aged 18-75 at the time of enrollment\n* Primary diagnosis of MDD as defined by the DSM-5\n* Determined by the clinic to be eligible for accelerated rTMS treatment and agrees to receive accelerated rTMS treatment\n* Agrees to start accelerated rTMS treatment in conjunction with study participation to capture baseline measurements\n* Has not received rTMS treatment in the past 1 month\n* Has not received SPRAVATO treatment in the past 1 month\n* Can speak and understand English\n* Ability to provide informed consent\n\nHealthy controls cohort\n\n* Adults aged 18-75 at time of enrollment\n* Can speak and understand English\n* Ability to provide informed consent\n\nExclusion Criteria for:\n\nAll cohorts\n\n* Pregnant or may become pregnant during the treatment course\n* Unable or unwilling to wear the fNIRS headset\n* Has had electroconvulsive therapy (ECT) in the past 3 months\n* Major medical illnesses including neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, schizophrenia, or stroke.\n* Any other clinically significant medical condition that in the opinion of the clinician or study team, could affect patient safety, wellbeing, or the participant's ability to comply with study procedures.\n* Not an appropriate candidate for the study based on the discretion of the study investigator(s).\n\nHealthy controls cohort only\n\n* Clinical diagnosis of depression in the past year\n* Undergoing any treatments for depression in the past year",true,"ALL","18 Years","75 Years",{"count":83,"type":84},100,"ESTIMATED","OBSERVATIONAL","This observational, longitudinal, multi-cohort study aims to evaluate functional brain activity in adults undergoing treatment for Major Depressive Disorder (MDD) at participating clinical sites. A separate cohort of healthy adults will be enrolled as a control group. All data collected in this study are for research purposes only and will not influence clinical decision-making or treatment plans.\n\nThis study will use TD-fNIRS to measure hemodynamic brain responses at rest and\u002For during tasks in patients receiving accelerated transcranial magnetic stimulation (TMS). Imaging will occur at multiple timepoints (pre-treatment, post-treatment, and follow-ups). Healthy control participants will complete similar measurements at one visit, with the option for a follow-up visit. The primary objectives are to assess feasibility, characterize brain activity patterns, and explore potential biomarkers associated with treatment response.",[88,89],"Major Depressive Disorder (MDD)","fNIRS",[91,92,93,94,95],"Accelerated TMS","Healthy Controls","Observational","Longitudinal","Neuroimaging","2025-12-08",{"date":98,"type":99},"2025-12-19","ACTUAL",{"date":101,"type":84},"2025-12-15",{"date":103,"type":84},"2026-12-15",{"name":5,"class":6},2]